Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies and as Risk Recurrence Factors in Stage II Colon Cancer.

Fiche publication

Date publication

décembre 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOUVIER Anne-Marie , Dr CHAPUSOT Caroline , Pr GHIRINGHELLI François , Dr JOOSTE Valérie , Pr LEPAGE Côme , Pr MARTIN Laurent , Mme TRUNTZER Caroline , Pr MANFREDI Sylvain , Pr CALLANAN Mary , Dr AUCAGNE Romain

Tous les auteurs :
Tournier B, Aucagne R, Truntzer C, Fournier C, Ghiringhelli F, Chapusot C, Martin L, Bouvier AM, Manfredi S, Jooste V, Callanan MB, Lepage C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36612154

Résumé

Stage II colon cancer (CC), although diagnosed early, accounts for 16% of CC deaths. Predictors of recurrence risk could mitigate this but are currently lacking. By using a DNA methylation-based clinical screening in real-world ( = 383) and in TCGA-derived cohorts of stage II CC ( = 134), we have devised a novel 40 CpG site-based classifier that can segregate stage II CC into four previously undescribed disease sub-classes that are characterised by distinct molecular features, including activation of MYC/E2F-dependant proliferation signatures. By multivariate analyses, hypermethylation of 2 CpG sites at genes and , respectively, was found to independently confer either significantly increased (; -value, 0.0203) or reduced (; -value, 0.0047) risk of CC recurrence. Functional enrichment and immune cell infiltration analyses, on RNAseq data from the TCGA cohort, revealed cases with hypermethylation at to be enriched for , epithelial-mesenchymal transition and inflammatory functions (via IL2/STAT5), associated with infiltration by 'exhausted' T cells. By contrast, hypermethylated cases showed enrichment for mTORC1, DNA repair pathways and activated B cell signatures. These findings will be of value for improving personalised care paths and treatment in stage II CC patients.